US 12,324,836 B2
Methods and compositions for vaccinating and boosting cancer patients
Lawrence G. Lum, Sunnyvale, CA (US); and Manley Huang, Sunnyvale, CA (US)
Assigned to TRANSTARGET, INC., Sunnyvale, CA (US)
Appl. No. 16/467,003
Filed by TransTarget, Inc., Sunnyvale, CA (US)
PCT Filed Dec. 7, 2017, PCT No. PCT/US2017/065177
§ 371(c)(1), (2) Date Jun. 5, 2019,
PCT Pub. No. WO2018/106958, PCT Pub. Date Jun. 14, 2018.
Claims priority of provisional application 62/497,879, filed on Dec. 7, 2016.
Prior Publication US 2019/0343954 A1, Nov. 14, 2019
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01)
CPC A61K 39/39558 (2013.01) [A61K 40/11 (2025.01); A61K 40/4205 (2025.01); C07K 16/2809 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); A61K 2039/515 (2013.01); A61K 2039/545 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/49 (2023.05); C07K 2317/31 (2013.01)] 14 Claims
 
1. A method of improving the immunotherapeutic response of a cancer patient vaccinated with a cancer specific T cell, the method comprising steps of:
i. Vaccinating a cancer patient with a cancer specific T-cell vaccine cell population comprising T-cells in an amount sufficient to prime immune specific anti-tumor T-cells of the cancer patient, wherein the cancer specific T-cell vaccine cell population is bispecific antibody armed activated T-cells (BATs), Chimeric Antigen Receptor T-cells (CAR-T), Tumor infiltrating lymphocytes (TILs), T-cell receptor engineered T cells (TCR transgenic), or bispecific antibody armed T-Rapa cells;
ii. Collecting the primed immune specific anti-tumor T-cells from the peripheral blood of the cancer patient;
iii. Culturing the collected primed immune specific anti-tumor T cells ex vivo in a medium with anti-CD3 or with anti-CD3 and anti-CD28 antibodies, wherein the collected primed immune specific anti-tumor T cells are expanded;
iv. Testing the cultured collected primed immune specific anti-tumor T cells for cytotoxicity and comparing the cultured collected primed immune specific anti-tumor T cells cytotoxicity to cytotoxicity of ex-vivo cultured activated T-cells of the pre-vaccination patient; and
v. Upon determining that the collected primed immune specific anti-tumor T cells cytotoxicity exceeds ex-vivo cultured activated T-cells of the pre-vaccination patient cytotoxicity, reinfusing the cultured primed immune specific anti-tumor T cells into the cancer patient in vivo, wherein the reinfused T-cells are not genetically modified and not armed with at least a portion of an antibody, and wherein the cancer patient is treated with neither IL-2 nor GM-CSF during the steps i-v.